Claims for Patent: 9,005,903

Summary for Patent: 9,005,903

Title:	Immunomodulating compositions and methods of use thereof
Abstract:	The invention is directed to .beta.1-6 glucans, compositions, diagnostic kits, and devices comprising the same, and methods of use thereof in modulating immune response and treating, delaying progression of, reducing the incidence or severity of cancer, infection, inflammation, and autoimmune diseases. The .beta.1-6 glucans of certain embodiments of the invention are enriched for O-acetylated groups and/or conjugated to a solid support or linked to a targeting moiety. The .beta.1-6 glucans of certain embodiments of the invention recruit immunoglobulin G antibodies to mediate complement and neutrophil killing. The conjugated .beta.1-6 glucans of certain embodiments of the invention are targeted to cells to stimulate the immune response at the target location by activating complement-mediated lysis and recruitment of neutrophils.
Inventor(s):	Rubin-Bejerano; Ifat (Newton, MA), Fink; Gerald R. (Chestnut Hill, MA)
Assignee:	ImmuneXcite, Inc. (Lexington, MA)
Application Number:	14/103,015
Patent Claims:	1. A method of treating a subject with a vaccine, adjuvant or composition comprising .beta.-1,6-glucan, the method comprising purified, isolated, or synthesized administering a vaccine, adjuvant or composition comprising purified, isolated, or synthesized .beta.-1,6-glucan to a subject, wherein the subject has previously been determined to possess a higher titer of IgG1 or IgG2 or IgG3, or a combination thereof, versus a titer of IgG4 to .beta.-1,6-glucan. 2. The method of claim 1, wherein the subject has previously been determined to possess a higher titer of IgG2 versus IgG4 to .beta.-1,6-glucan. 3. The method of claim 1, wherein the vaccine, adjuvant or composition comprises .beta.-1,6-glucan linked to an antibody. 4. The method of claim 3, wherein the antibody is a monoclonal antibody. 5. The method of claim 3, wherein the antibody is a human antibody. 6. The method of claim 3, wherein the antibody is a humanized antibody. 7. The method of claim 3, wherein the antibody is an antibody fragment. 8. The method of claim 7, wherein the antibody fragment is a Fab fragment, Fab' fragment, (Fab').sub.2 fragment, Fv fragment, a single chain antibody or a peptide coding for a single complementarity-determining region. 9. The method of claim 3, wherein the antibody is selected from the group consisting of Alemtuzumab, Bevacizumab, Cetuximab, Gemtuzumab, Ibritumomab, Panitumumab, Rituximab, Tositumomab, Trastuzumab and Palivizumab. 10. The method of claim 3, wherein the antibody targets a neoplastic or preneoplastic cell. 11. The method of claim 10, wherein the vaccine, adjuvant or composition comprising .beta.-1,6-glucan promotes a host anticancer response. 12. The method of claim 10, wherein the vaccine, adjuvant or composition comprising .beta.-1,6-glucan promotes tumor cell lysis. 13. The method of claim 10, wherein the vaccine, adjuvant or composition comprising .beta.-1,6-glucan enhances a host antitumor response. 14. The method of claim 3, wherein the antibody targets an antigen expressed specifically on cancer cells. 15. The method of claim 14, wherein the vaccine, adjuvant or composition comprising .beta.-1,6-glucan enhances complement-mediated lysis of the cancer cells. 16. A method of treating a subject with a vaccine, adjuvant or composition comprising purified, isolated, or synthesized .beta.-1,6-glucan, the method comprising: administering an agent to a subject which biases antibody production to yield relatively greater amounts of IgG1 or IgG2 or IgG3, or a combination thereof, versus IgG4, wherein the subject has previously been determined to possess a lower titer of IgG1 or IgG2 or IgG3, or a combination thereof, versus IgG4 to .beta.-1,6-glucan; and administering a vaccine, adjuvant or composition comprising purified, isolated, or synthesized .beta.-1,6-glucan to the subject when the subject possesses a higher titer of IgG1 or IgG2 or IgG3, or a combination thereof, versus a titer of IgG4 to .beta.-1,6-glucan. 17. The method of claim 16, wherein the agent is selected from the group consisting of cytokines, chemokines, complement components, immune system accessory and adhesion molecules and receptors of any of these. 18. The method of claim 17 wherein the agent is selected from the group consisting of interleukin 2, interleukin 12, interferon-gamma and combinations thereof. 19. The method of claim 16, wherein the agent is administered based on a determination that the subject possesses a lower titer of IgG2 versus IgG4 to .beta.-1,6-glucan. 20. The method of claim 3, wherein the composition is a pharmaceutical composition. 21. The method of claim 1, wherein the vaccine, adjuvant or composition comprises .beta.-1,6-glucan linked to an aptamer. 22. The method of claim 1, wherein the vaccine, adjuvant or composition comprises .beta.-1,6-glucan linked to a peptide. 23. A method of treating a subject with a vaccine, adjuvant or composition comprising purified, isolated, or synthesized .beta.-1,6-glucan, the method comprising identifying a subject that possesses a higher titer of IgG1 or IgG2 or IgG3, or a combination thereof, versus a titer of IgG4 to .beta.-1,6-glucan and administering a vaccine, adjuvant or composition comprising purified, isolated, or synthesized .beta.-1,6-glucan to the subject. 24. The method of claim 23, wherein the subject possesses a higher titer of IgG2 versus IgG4 to .beta.-1,6-glucan. 25. The method of claim 24, wherein the vaccine, adjuvant or composition comprises .beta.-1,6-glucan linked to an antibody. 26. The method of claim 25, wherein the composition is a pharmaceutical composition. 27. A method of treating a subject with a vaccine, adjuvant or composition comprising purified, isolated, or synthesized .beta.-1,6-glucan, the method comprising administering a vaccine, adjuvant or composition comprising purified, isolated, or synthesized .beta.-1,6-glucan to a subject, wherein the subject has previously been determined to possess a level of IgG2 titer to .beta.-1,6-glucan above a threshold. 28. The method of claim 27, wherein the vaccine, adjuvant or composition comprises .beta.-1,6-glucan linked to an antibody. 29. The method of claim 28, wherein the composition is a pharmaceutical composition. 30. A method of treating a subject with a vaccine, adjuvant or composition comprising purified, isolated, or synthesized .beta.-1,6-glucan, the method comprising identifying a subject that possesses a level of IgG2 titer to .beta.-1,6-glucan above a threshold and administering a vaccine, adjuvant or composition comprising purified, isolated, or synthesized .beta.-1,6-glucan to the subject. 31. The method of claim 30, wherein the vaccine, adjuvant or composition comprises .beta.-1,6-glucan linked to an antibody. 32. The method of claim 31, wherein the composition is a pharmaceutical composition. 33. The method of claim 1, wherein the .beta.-1,6-glucan is chemically or enzymatically synthesized. 34. The method of claim 1, wherein the .beta.-1,6-glucan is genetically engineered. 35. The method of claim 1, wherein the .beta.-1,6-glucan is chemically or enzymatically altered. 36. The method of claim 16, wherein the .beta.-1,6-glucan is chemically or enzymatically synthesized. 37. The method of claim 16, wherein the .beta.-1,6-glucan is genetically engineered. 38. The method of claim 16, wherein the .beta.-1,6-glucan is chemically or enzymatically altered. 39. The method of claim 23, wherein the .beta.-1,6-glucan is chemically or enzymatically synthesized. 40. The method of claim 23, wherein the .beta.-1,6-glucan is genetically engineered. 41. The method of claim 23, wherein the .beta.-1,6-glucan is chemically or enzymatically altered. 42. The method of claim 27, wherein the .beta.-1,6-glucan is chemically or enzymatically synthesized. 43. The method of claim 27, wherein the .beta.-1,6-glucan is genetically engineered. 44. The method of claim 27, wherein the .beta.-1,6-glucan is chemically or enzymatically altered. 45. The method of claim 30, wherein the .beta.-1,6-glucan is chemically or enzymatically synthesized. 46. The method of claim 30, wherein the .beta.-1,6-glucan is genetically engineered. 47. The method of claim 30, wherein the .beta.-1,6-glucan is chemically or enzymatically altered.

Details for Patent 9,005,903

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2028-04-29
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002		2028-04-29
Swedish Orphan Biovitrum Ab (publ)	SYNAGIS	palivizumab	For Injection	103770	06/19/1998		2028-04-29
Swedish Orphan Biovitrum Ab (publ)	SYNAGIS	palivizumab	Injection	103770	07/23/2004		2028-04-29
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2028-04-29
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2028-04-29
Genzyme Corporation	CAMPATH	alemtuzumab	Injection	103948	05/07/2001		2028-04-29